CA2405479C - Method of inhibiting the expression of inflammatory cytokines and chemokines - Google Patents

Method of inhibiting the expression of inflammatory cytokines and chemokines Download PDF

Info

Publication number
CA2405479C
CA2405479C CA2405479A CA2405479A CA2405479C CA 2405479 C CA2405479 C CA 2405479C CA 2405479 A CA2405479 A CA 2405479A CA 2405479 A CA2405479 A CA 2405479A CA 2405479 C CA2405479 C CA 2405479C
Authority
CA
Canada
Prior art keywords
astaxanthin
chemokines
expression
inflammatory cytokines
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2405479A
Other languages
English (en)
French (fr)
Other versions
CA2405479A1 (en
Inventor
Tove Andersson
Sven Pettersson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astareal AB
Original Assignee
Astacarotene AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astacarotene AB filed Critical Astacarotene AB
Publication of CA2405479A1 publication Critical patent/CA2405479A1/en
Application granted granted Critical
Publication of CA2405479C publication Critical patent/CA2405479C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Toxicology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2405479A 2000-03-27 2001-03-21 Method of inhibiting the expression of inflammatory cytokines and chemokines Expired - Fee Related CA2405479C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0001071-0 2000-03-27
SE0001071A SE0001071D0 (sv) 2000-03-27 2000-03-27 Method of inhibiting the expression of inflammatory cytokines and chemokines
PCT/SE2001/000600 WO2001072296A1 (en) 2000-03-27 2001-03-21 Method of inhibiting the expression of inflammatory cytokines and chemokines

Publications (2)

Publication Number Publication Date
CA2405479A1 CA2405479A1 (en) 2001-10-04
CA2405479C true CA2405479C (en) 2010-11-16

Family

ID=20279020

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2405479A Expired - Fee Related CA2405479C (en) 2000-03-27 2001-03-21 Method of inhibiting the expression of inflammatory cytokines and chemokines

Country Status (8)

Country Link
EP (1) EP1267857B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003528139A (cg-RX-API-DMAC7.html)
AT (1) ATE353639T1 (cg-RX-API-DMAC7.html)
AU (1) AU2001242965A1 (cg-RX-API-DMAC7.html)
CA (1) CA2405479C (cg-RX-API-DMAC7.html)
DE (1) DE60126591D1 (cg-RX-API-DMAC7.html)
SE (1) SE0001071D0 (cg-RX-API-DMAC7.html)
WO (1) WO2001072296A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003048202A2 (en) * 2001-12-03 2003-06-12 Asahi Kasei Pharma Corporation Nf-kappab activating genes
EP2653157B1 (en) * 2004-02-04 2016-08-03 Fuji Chemical Industry Co., Ltd. Astaxanthin for improving muscle atrophy
JP2006008714A (ja) * 2005-03-17 2006-01-12 Yamaha Motor Co Ltd マトリックスメタロプロテイナーゼ阻害剤
JP2006008718A (ja) * 2005-06-03 2006-01-12 Yamaha Motor Co Ltd シクロオキシゲナーゼ活性阻害剤
JP2006008719A (ja) * 2005-06-23 2006-01-12 Yamaha Motor Co Ltd 血中過酸化脂質抑制剤
US7805004B2 (en) * 2007-02-28 2010-09-28 Microsoft Corporation Radical set determination for HMM based east asian character recognition
WO2008106606A2 (en) * 2007-02-28 2008-09-04 Cardax Pharmaceuticals, Inc. Carotenoid analogs and derivatives in the treatment of prostate cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05155736A (ja) * 1991-12-10 1993-06-22 Nakano Seiyaku Kk 化粧料
JPH0799924A (ja) * 1993-09-30 1995-04-18 Nippon Suisan Kaisha Ltd アスタキサンチンを主要成分とするファフィア色素油の安定な粉末化物及びその製造方法
JPH07300421A (ja) * 1994-04-28 1995-11-14 Itano Reitou Kk 抗炎症剤
US5527533A (en) * 1994-10-27 1996-06-18 Board Of Trustees Of The University Of Illinois Method of retarding and ameliorating central nervous system and eye damage
US5886053A (en) * 1995-02-03 1999-03-23 Basf Aktiengesellschaft Use of carotenoids for producing drugs for the treatment of dermatoses
JPH09124470A (ja) * 1995-10-26 1997-05-13 Suntory Ltd 抗ストレス組成物
JPH09143063A (ja) * 1995-11-22 1997-06-03 Kose Corp 外用に適する組成物
SE522246C2 (sv) * 1997-02-27 2004-01-27 Astacarotene Ab Oralt preparat för profylaktisk och terapeutisk behandling av Helicobacter Sp. infektion
EP0984915A4 (en) * 1997-04-04 2002-11-27 Henkel Corp LUTEINE ESTERS WITH HIGH BIOAVAILABILITY
SE512531C2 (sv) * 1997-09-04 2000-03-27 Astacarotene Ab Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk förbättring av muskelfunktionsdurationen hos däggdjur och/eller behandling av muskelstörningar eller - sjukdomar hos däggdjur

Also Published As

Publication number Publication date
SE0001071D0 (sv) 2000-03-27
DE60126591D1 (de) 2007-03-29
ATE353639T1 (de) 2007-03-15
AU2001242965A1 (en) 2001-10-08
CA2405479A1 (en) 2001-10-04
EP1267857A1 (en) 2003-01-02
WO2001072296A1 (en) 2001-10-04
JP2003528139A (ja) 2003-09-24
EP1267857B1 (en) 2007-02-14

Similar Documents

Publication Publication Date Title
Li et al. Synergistic anti‐inflammatory effects of quercetin and catechin via inhibiting activation of TLR4–MyD88‐mediated NF‐κB and MAPK signaling pathways
Barbarestani et al. Effects of dietary lavender essential oil on growth performance, intestinal function, and antioxidant status of broiler chickens
Choe et al. The science behind microgreens as an exciting new food for the 21st century
Ay et al. Molecular mechanisms underlying protective effects of quercetin against mitochondrial dysfunction and progressive dopaminergic neurodegeneration in cell culture and MitoPark transgenic mouse models of Parkinson's Disease
Kang et al. Inhibition of inducible nitric-oxide synthase expression by silymarin in lipopolysaccharide-stimulated macrophages
Saihara et al. Pyrroloquinoline quinone, a redox-active o-quinone, stimulates mitochondrial biogenesis by activating the SIRT1/PGC-1α signaling pathway
Ables et al. Pleiotropic responses to methionine restriction
Wu et al. Effect of choline on antioxidant defenses and gene expressions of Nrf2 signaling molecule in the spleen and head kidney of juvenile Jian carp (Cyprinus carpio var. Jian)
Yang et al. Activation of Nrf2 by phloretin attenuates palmitic acid-induced endothelial cell oxidative stress via AMPK-dependent signaling
Wang et al. Seaweed extracts and unsaturated fatty acid constituents from the green alga Ulva lactuca as activators of the cytoprotective Nrf2–ARE pathway
Yang et al. Green tea polyphenols block endotoxin-induced tumor necrosis factor-production and lethality in a murine model
Wan et al. Protective effects of lycopene on mitochondrial oxidative injury and dysfunction in the liver of aflatoxin B1-exposed broilers
US7078040B2 (en) Method of inhibiting the expression of inflammatory cytokines and chemokines
Deng et al. Magnolol and honokiol regulate the calcium-activated potassium channels signaling pathway in Enterotoxigenic Escherichia coli-induced diarrhea mice
Liu et al. Cytochrome P450 enzymes mediated by DNA methylation is involved in deoxynivalenol-induced hepatoxicity in piglets
Martorana et al. Differential Modulation of NF‐κB in Neurons and Astrocytes Underlies Neuroprotection and Antigliosis Activity of Natural Antioxidant Molecules
Jiang et al. Impairment of gill structural integrity by manganese deficiency or excess related to induction of oxidative damage, apoptosis and dysfunction of the physical barrier as regulated by NF-κB, caspase and Nrf2 signaling in fish
Lauridsen et al. Composition of α-tocopherol and fatty acids in porcine tissues after dietary supplementation with vitamin E and different fat sources
Meng et al. β-carotene alleviates LPS-induced inflammation through regulating STIM1/ORAI1 expression in bovine mammary epithelial cells
Li et al. Ellagic acid alters muscle fiber-type composition and promotes mitochondrial biogenesis through the AMPK signaling pathway in healthy pigs
Lee et al. Effect of dietary supplementation of the combination of gallic and linoleic acid in thigh meat of broilers
Oravetz et al. Potential antitumor activity of garlic against colorectal cancer: focus on the molecular mechanisms of action
Zhao et al. Blueberry polyphenol extracts enhance the intestinal antioxidant capacity in weaned rats by modulating the nrf2–keap1 signal pathway
EP1267857B1 (en) In vitro use of astaxanthin for pretreatment of cells prior to UV-exposure to inhibit the activation of NF-kB
Arif et al. Physiological and morphological impact of physical activity and nutritional interventions to offset disuse-induced skeletal muscle atrophy

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20180321